GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
GRAIL, Inc. launched an at‑the‑market offering of up to $300,000,000 in common stock under a prospectus supplement to its shelf registration. Sales may be made from time to time through Morgan Stanley & Co. LLC and TD Securities (USA) LLC as sales agents or principals in transactions deemed an “at the market offering” on Nasdaq or otherwise at market-related or negotiated prices.
The sales agents will earn up to 3.0% of the gross sales price per share. Proceeds will go to GRAIL, and the company currently intends to use the net proceeds to fund commercial activities and reimbursement efforts, as well as for working capital and other general corporate purposes.
GRAIL’s common stock trades on Nasdaq as “GRAL”; the last reported sale price was $83.20 per share on November 13, 2025. Shares outstanding were 36,160,998 as of September 30, 2025. Under the equity distribution agreement, the total number of shares sold pursuant to the program will not exceed 6,900,000.
GRAIL, Inc. filed a prospectus supplement for the resale of up to 3,925,767 shares of common stock by selling stockholders. The registration covers 1,927,194 outstanding common shares and 1,998,573 shares issuable upon exercise of pre-funded warrants.
The company is not selling shares and will not receive proceeds from holder sales; it would receive the nominal $0.001 per-share exercise price if pre-funded warrants are exercised for cash. Selling holders may use various methods of sale, including brokerage transactions, block trades, privately negotiated deals and short sales after the registration statement is declared effective.
Examples include Deep Track Biotechnology Master Fund, Ltd. 927,909 and Farallon affiliates 571,021. Shares outstanding were 38,981,593 as of October 31, 2025. GRAL trades on Nasdaq Global Select Market; the last reported sale price was $84.77 on November 12, 2025.
GRAIL, Inc. (GRAL) reported Q3 2025 results. Total revenue was $36,194 (thousands), up from $28,652 (thousands) a year ago, driven mainly by screening revenue of $32,807 (thousands). Net loss narrowed to $88,977 (thousands), or $2.46 per share, from $125,688 (thousands) a year earlier as operating expenses declined.
Cash and cash equivalents were $126,892 (thousands) and short‑term marketable securities were $413,238 (thousands) as of September 30, 2025. Year‑to‑date, operating cash use was $235,222 (thousands). Management states existing cash, cash equivalents, and short‑term marketable securities will be sufficient for at least the next 12 months. Total assets were $2,601,031 (thousands) with stockholders’ equity of $2,239,963 (thousands). As of November 10, 2025, common shares outstanding were 38,982,223.
GRAIL, Inc. entered into a Securities Purchase Agreement for a private placement of 4,639,543 shares of common stock (or pre-funded warrants with a $0.001 exercise price) at $70.05 per share, for approximate gross proceeds of $325.0 million. Closing is expected on October 21, 2025.
The pre-funded warrants are immediately exercisable and include a Beneficial Ownership Limitation of 4.99% or 9.99% (holder election), which may be increased upon 61 days’ notice up to 19.99%. GRAIL agreed to file a resale registration statement within 30 days after closing and use reasonable best efforts to obtain effectiveness within 60 days of filing or within 5 business days after an SEC no-review notice. The transaction is exempt under Section 4(a)(2) and Regulation D.
GRAIL, Inc. entered into a Securities Purchase Agreement for a private placement of 4,639,543 shares of common stock (or pre-funded warrants with a $0.001 exercise price) at $70.05 per share, for approximate gross proceeds of $325.0 million. Closing is expected on October 21, 2025.
The pre-funded warrants are immediately exercisable and include a Beneficial Ownership Limitation of 4.99% or 9.99% (holder election), which may be increased upon 61 days’ notice up to 19.99%. GRAIL agreed to file a resale registration statement within 30 days after closing and use reasonable best efforts to obtain effectiveness within 60 days of filing or within 5 business days after an SEC no-review notice. The transaction is exempt under Section 4(a)(2) and Regulation D.
GRAIL, Inc. (GRAL) disclosed a routine director equity grant. On October 15, 2025, director William Chase received 275 deferred stock units in lieu of $20,794.52 of cash director fees, valued at $75.52 per share, the closing price that day. The awards vest immediately upon grant. After the transaction, his beneficial ownership was 36,590 shares, held directly.
GRAIL, Inc. agreed to a private placement with Samsung C&T and Samsung Electronics Singapore for 1,570,308 common shares at $70.05 per share, pursuant to a Stock Purchase Agreement. Closing is conditioned on regulatory clearances, including CFIUS, and execution by January 31, 2026 of a business collaboration with Samsung C&T for exclusive Galleri commercialization in Korea and a strategic collaboration with Samsung Electronics.
The company plans to use net proceeds for general corporate purposes to support commercialization and reimbursement efforts. GRAIL will file a resale registration covering the shares within 180 days after closing.
GRAIL also disclosed preliminary Q3 2025 results: US screening revenue between $32.1–$33.1 million, total revenue between $35.7–$36.7 million, and losses from operations between $123.9–$126.9 million. Cash, cash equivalents, restricted cash and short-term marketable securities were approximately $547 million as of September 30, 2025. These figures are preliminary and unaudited.
GRAIL, Inc. (GRAL) reported insider stock sales by President Joshua Ofman on a Form 4. On 10/15/2025, he sold 8,865 shares of common stock at an average price of $76.0276. On 10/16/2025, he sold 6,114 shares at an average price of $82.01.
Following these transactions, Ofman beneficially owns 381,818 shares directly. The filing notes the sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
GRAIL, Inc. (GRAL) reported a director equity grant. On 10/15/2025, Director Steven Mizell acquired 267 deferred stock units under the company’s deferred stock program and 2024 Equity Incentive Plan. The grant was issued in lieu of $20,164.38 of cash fees, using a price per share of $75.52 (the closing price on the grant date). The awards vest immediately upon grant. Following this transaction, the director beneficially owned 36,469 shares, held directly.
GRAIL, Inc. (GRAL) reported a director equity grant on Form 4. On October 15, 2025, director Gregory Summe received 425 deferred stock units under the company’s deferred stock program and 2024 Equity Incentive Plan in lieu of $32,136.99 of cash director fees, based on the $75.52 closing price of the company’s common stock on the grant date. The awards vest immediately.
Following this transaction, Mr. Summe beneficially owned 38,794 shares, held directly.
GRAIL, Inc. (GRAL) reported an insider transaction on a Form 4. CEO and director Robert Ragusa executed an automatic sell-to-cover of 7,239 shares of common stock on 10/15/2025 at a weighted average price of $68.88 to cover withholding taxes upon award vesting and share delivery.
After the transaction, Ragusa beneficially owned 727,388 shares, held directly. The sale was reported under transaction code “S” and occurred as part of a block trade executed in multiple transactions.